Ocular herpes simplex.
BACKGROUND
Ocular infection with herpes simplex virus (HSV) is usually acquired early in life, with 50% of people from higher and 80% from lower socioeconomic groups in the USA having antibodies by the age of 30 years. Attacks usually resolve spontaneously within 1-2 weeks, but 50% of people will experience a recurrence within 10 years.


METHODS
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments in people with epithelial keratitis? What are the effects of treatments in people with stomal keratitis? What are the effects of interventions to prevent recurrence of ocular herpes simplex? What are the effects of interventions to prevent recurrence of ocular herpes simplex in people with corneal grafts? We searched: Medline, Embase, The Cochrane Library, and other important databases up to July 2007 (BMJ Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).


RESULTS
We found seven systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.


CONCLUSIONS
In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding oral aciclovir to topical corticosteroids plus topical antiviral treatment; adding topical corticosteroids to topical antiviral treatment; antiviral agents (topical); debridement; interferons (topical); and oral aciclovir.
Barker
Nigel H
NH
Warrens Eye Care Centre, Manor Lodge, St Michael, Barbados.
D000208:Acute Disease; D000212:Acyclovir / Q000008:administration & dosage; D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage; D003646:Debridement; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D016849:Keratitis, Herpetic / Q000188:drug therapy; D012008:Recurrence
D000998:Antiviral Agents; D007372:Interferons; D000212:Acyclovir